MCL1 and hematopoietic and lymphoid cell neoplasm: Other Mcl-1 inhibitors under active consideration for use in RRMM as well as other hematologic cancers include S-64315/MIK665 (NCT02992483) [111], PRT1419 (NCT04543305) [112], and AZD-5991 (NCT03218683) [113].